Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 05, 2025, titled "Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer".
Press Release Sep 05 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Press Release Sep 02 2025
- Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials
- FY 2024-25
- Q1FY 2025-26
- Press Release Aug 19 2025
Later from Glenmark Pharmaceuticals
- Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)
- Press Release Sep 24 2025
- Glenmark Pharmaceuticals Limited Press Release Oct 23 2025
- Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials
- Glenmark Pharmaceuticals Limited Press Release Nov 04 2025
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals